Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection

• Status: Not yet recruiting
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate efficacy of a 14-day concomitant therapy for the third-line treatment of Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shandong University
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular

Criteria

Inclusion Criteria:

• Patients aged 18-70 years were recruited for this study if they had failed at least three rounds of anti- H. pylori therapies. The presence of H. pylori was defined as any two positive outcomes of 13C- urea breath test, rapid urease test, a positive result of culture or histopathology.

Exclusion Criteria:

• (1) Patients treated with H2-receptor antagonist, PPI, vonoprazan, bismuth and antibiotics in the previous 4 weeks, (2) Patients with gastorectomy, acute GI bleeding and advanced gastric cancer, (3) History of allergy to any of the drugs used in the study, (4) Severe concomitant cardiovascular, respiratory, or endocrine diseases, clinically significant renal or hepatic disease, hematologic disorders and any other clinically significant medical condition that could increase risk, (5) Currently pregnant or lactating, (6) Severe neurologic or psychiatric disorders, (7)Alcohol abuse or drug addiction, (8)Patients with compliance lower than 90% in any previous treatment,（9）Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.